Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects

Nutrition Research

Volumn 29, Issue 3, 2009, Pages 190-196

  Hsia, Chien Hsun ^a   Shen, Ming Ching ^a   Lin, Jen Shiou ^a   Wen, Yao Ke ^a   Hwang, Kai Lin ^b   Cham, Thau Ming ^c   Yang, Nae Cherng ^d  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG CHOU INSTITUTE OF TECHNOLOGY   (Taiwan)

Author keywords

Cardiovascular disease; Cholesterol; Factor VII; Factor VIII; Fibrinogen; Human; Nattokinase

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; GELATIN; LIPID; NATTOKINASE; NUTRACEUTICAL; SERINE PROTEINASE; UNCLASSIFIED DRUG; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CAPSULE ENDOSCOPE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIALYSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LABORATORY TEST; LIPID BLOOD LEVEL; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; SELF CONTROL; TREATMENT DURATION; URIC ACID BLOOD LEVEL;

ADULT; AGED; CHOLESTEROL; FACTOR VII; FACTOR VIII; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; SUBTILISINS; YOUNG ADULT;

BACILLUS SUBTILIS;

EID: 63549131349     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2009.01.009     Document Type: Article

References (35)

1. Tai M.W., and Sweet B.V. Nattokinase for prevention of thrombosis. Am J Health Syst Pharm 63 (2006) 1121-1123
2. Urano T., Ihara H., Umemura K., Suzuki Y., Oike M., Akita S., et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem 276 (2001) 24690-24696
3. Sumi H., Hamada H., Tsushima H., Mihara H., and Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia 43 (1987) 1110-1111
4. Fujita M., Nomura K., Hong K., Ito Y., Asada A., and Nishimuro S. Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan. Biochem Biophys Res Commun 197 (1993) 1340-1347
5. Fujita M., Hong K., Ito Y., Fujii R., Kariya K., and Nishimuro S. Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat. Biol Pharm Bull 18 (1995) 1387-1391
6. Sumi H., Hamada H., Nakanishi K., and Hiratani H. Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol 84 (1990) 139-143
7. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 89 (2003) 601-609
8. Lefevre M., Kris-Etherton P.M., Zhao G., and Tracy R.P. Dietary fatty acids, hemostasis, and cardiovascular disease risk. J Am Diet Assoc 104 (2004) 410-419 [quiz 492]
9. Kannel W.B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40 (2005) 1215-1220
10. Eidelman R.S., and Hennekens C.H. Fibrinogen: a predictor of stroke and marker of atherosclerosis. Eur Heart J 24 (2003) 499-500
11. Canseco-Avila L.M., Jerjes-Sánchez C., Ortiz-López R., Rojas-Martínez A., and Guzmán-Ramírez D. Fibrinogen. Cardiovascular risk factor or marker?. Arch Cardiol Mex 76 (2006) S158-S172
12. Cushman M., Yanez D., Psaty B.M., Fried L.P., Heiss G., Lee M., et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators. Am J Epidemiol 143 (1996) 665-676
13. Tracy R.P., Arnold A.M., Ettinger W., Fried L., Meilahn E., and Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 19 (1999) 1776-1783
14. Kamphuisen P.W., Eikenboom J.C., and Bertina R.M. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 21 (2001) 731-738
15. Nicolosi R.J., Wilson T.A., Lawton C., and Handelman G.J. Dietary effects on cardiovascular disease risk factors: beyond saturated fatty acids and cholesterol. J Am Coll Nutr (2001) 421S-427S [discussion 440S-442S]
16. Després J.P., Arsenault B.J., Côté M., Cartier A., and Lemieux I. Abdominal obesity: the cholesterol of the 21st century?. Can J Cardiol 24 Suppl D (2008) 7D-12D
17. Arsenault B.J., Pibarot P., and Després J.P. The quest for the optimal assessment of global cardiovascular risk: are traditional risk factors and metabolic syndrome partners in crime?. Cardiology 113 (2008) 35-49
18. Iwai K., Nakaya N., Kawasaki Y., and Matsue H. Antioxidative functions of natto, a kind of fermented soybeans: effect on LDL oxidation and lipid metabolism in cholesterol-fed rats. J Agric Food Chem 50 (2002) 3597-3601
19. Chow F.Y., Polkinghorne K.R., Chadban S.J., Atkins R.C., and Kerr P.G. Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology (Carlton) 8 (2003) 177-183
20. Bergesio F., Monzani G., Guasparini A., Ciuti R., Gallucci M., Cristofano C., et al. Cardiovascular risk factors in severe chronic renal failure: the role of dietary treatment. Clin Nephrol 64 (2005) 103-112
21. Garrel D.R., Verdy M., PetitClerc C., Martin C., Brule D., and Hamet P. Milk- and soy-protein ingestion: acute effect on serum uric acid concentration. Am J Clin Nutr 53 (1991) 665-669
22. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
23. Hollis S., and Campbell F. What is meant by intention to treat analysis? Survey of published randomized controlled trials. BMJ 319 (1999) 670-674
24. Rice J.A. A nonparametric method-the signed rank test. Mathematical statistics and data analysis (1988), Wadsworth & Brooks, Belmont 374-376
25. Rice J.A. A nonparametric method-the Kruskal-Wallis test. Mathematical statistics and data analysis (1988), Wadsworth & Brooks, Belmont 406-408
26. In: Dawson B., and Trapp R.G. (Eds). Multiple-comparison procedures. Basic & Clinical Biostatistics. 3rd ed. (2001), McGraw-Hill, Singapore 169-172
27. In: Dawson B., and Trapp R.G. (Eds). Multiple-comparison procedures. Small expected frequencies & Fisher's exact test. 3rd ed. (2001), McGraw-Hill, Singapore 169-172
28. Louis T.A. General methods for analysing repeated measures. Stat Med 7 (1988) 29-45
29. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarti R.R., North W.R., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2 (1986) 533-537
30. Duncan B.B., Schmidt M.I., Offenbacher S., Wu K.K., Savage P.J., and Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. Diabetes Care 22 (1999) 767-772
31. Taku K., Umegaki K., Sato Y., Taki Y., Endoh K., and Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 85 (2007) 1148-1156
32. Xiao C.W., Mei J., and Wood C.M. Effect of soy proteins and isoflavones on lipid metabolism and involved gene expression. Front Biosci 13 (2008) 2660-2673
33. Levine M.N., Raskob G., Landefeld S., and Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 114 (1998) 511S-523S
34. Lee A.Y., and Hirsh J. Diagnosis and treatment of venous thromboembolism. Annu Rev Med 53 (2002) 15-33
35. Landefeld C.S., and Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95 (1993) 315-328